T-Cell study funded

May 1, 2004

The National Institutes of Health (NIH) National Cancer Institute has granted $124,000 to Aastrom Biosciences, Inc. to develop an immunotherapeutic treatment of malignant melanoma using AastromReplicell System cell production technology.